BCRXMEDIUM SIGNALFINANCIAL10-K

BCRX shows improved financial position with substantially better equity position and reduced total liabilities, though inventory levels declined sharply and SG&A expenses grew meaningfully.

The company's balance sheet strengthened notably with stockholders' equity improving by 75% and total liabilities declining by over $300M, suggesting resolution of previous financial pressures or successful restructuring. However, the sharp inventory reduction of 83% alongside higher SG&A expenses may indicate operational challenges or strategic shifts in product focus.

Comparing 2026-02-26 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

BCRX's financial profile improved substantially with stockholders' equity moving from deeply negative to a less concerning position while total liabilities dropped by over $330M. The dramatic inventory decline from $31M to $5M stands out as potentially concerning for operational continuity, though this was partially offset by higher accounts receivable suggesting continued sales activity. SG&A expenses grew by 31% to $349M, indicating increased operational spending even as the overall balance sheet strengthened considerably.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
-82.7%
$31.3M$5.4M

Inventory drawn down 82.7% — strong sell-through or deliberate destocking; watch for supply constraints.

Stockholders Equity
Balance Sheet
+75%
-$475.9M-$119.2M

Equity base grew 75% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+35.1%
$79.1M$106.8M

Receivables surged 35.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
-34.5%
$966.4M$633.3M

Liabilities reduced 34.5% — deleveraging improves balance sheet strength and financial flexibility.

SG&A Expense
P&L
+31%
$266.1M$348.6M

SG&A up 31% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+22.2%
$160.4M$196.1M

Current liabilities rose 22.2% — increased short-term obligations, watch current ratio.

Cash & Equivalents
Balance Sheet
-14.3%
$104.7M$89.7M

Cash decreased 14.3% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-25
ADDED
We may not achieve sustained profitability, and we may need to raise additional capital in the future.
If we are unable to raise capital or obtain financing if and when needed, we may need to adjust our operations.
If the benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of our common stock may decline.
In addition, combining Astria with our business may be more difficult, costly or time consuming than expected and the combined company may fail to realize the anticipated benefits, cost savings and synergies of the Merger.
The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that either were not previously identified or were worse than expected, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.
+7 more — sign up free →
REMOVED
Government exercising any options under our current procurement contract, and our ability to execute any such order; additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners; the implementation of our business model, strategic plans for our business, products, product candidates and technology; our ability to establish and maintain collaborations or out-license rights to our products and product candidates; plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd.
We have incurred losses since our inception and may never achieve sustained profitability.
If we are unable to raise capital if and when needed, we may need to adjust our operations.
If we fail to obtain additional financing or acceptable partnership arrangements if and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.
There can be no assurance that our or our partners commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →